Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

The goal of this clinical trial is to evaluate the efficacity and safety of pembrolizumab and capecitabine on the invasive disease-free survival, in participants who have triple negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy associated with pembrolizumab.

Trial Details

NCT ID
NCT05973864
Phase
PHASE2
Sponsor
UNICANCER
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Pembrolizumab injection
  • Capecitabine tablets
  • Local radiotherapy
Locations (sample)
  • Amiens, France|49.9,2.3
  • Avignon, France|43.94834,4.80892
  • Bayonne, France|43.49316,-1.473
  • Besançon, France|47.24878,6.01815
  • Bordeaux, France|44.84124,-0.58046

Key Eligibility Criteria

  • Patients eligible for this study must meet ALL of the following criteria:
  • Patient must have signed a written informed consent prior to any trial specific procedures. When the patient is physically unable to give their wri…
  • Subject ≥18 years of age on day of signing informed consent form (ICF);
  • Histologically proven TNBC defined as follows:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →